Memantine Clonmel

Memantine, the active ingredient in Memantine Clonmel, is a NMDA receptor antagonist presented as an oral dosage form for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults. GNH USA supplies Memantine Clonmel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine acts on the glutamatergic pathway and is used in the management of dementia related to Alzheimer’s disease. - Alzheimer’s disease: improves cognition and functional abilities in patients with moderate to severe disease.

Memantine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness: mild to moderate sensation of light‑headedness. - Headache: transient cranial pain. - Constipation: reduced bowel movements. - Confusion: temporary disorientation. - Fatigue: feeling unusually tired. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: severe skin blistering. - Hepatic injury: abnormal liver function tests. - Suicidal thoughts: emergence of depressive ideation. - Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Renal impairment: assess kidney function and consider dose adjustment. - Hepatic impairment: use with caution; monitor liver enzymes. - History of seizures: monitor closely for increased seizure activity. - Concurrent NMDA agonists: avoid co‑administration to prevent antagonistic effects. - Pregnancy and breastfeeding: risk unknown; discuss benefits versus risks with a healthcare professional. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with other medications that affect the central nervous system or electrolyte balance.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity. - Ketamine: combined CNS depression and dissociative effects. - Other NMDA antagonists: heightened risk of neurological adverse events.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible enhancement of hypotensive effect. - Diuretics: increased risk of dehydration and electrolyte disturbances. - Anticholinergics: may worsen cognitive impairment.